Related Experiment Video
Updated: Sep 27, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Xin Yu1, Xianxiu Ji1, Chunxia Su1
1Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Abstract:
Multiple oncogenic molecular alterations have been discovered that serve as potential drug targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological features of common targets in NSCLC have been widely investigated, those of uncommon targets are still needed to be clarified. Human epidermal growth factor receptor 2 (HER2, ERBB2)-altered tumors represent a highly heterogeneous group of diseases, which consists of three distinct situations including mutation, amplification and overexpression. Compared with breast and gastric cancer, previous studies have shown modest and variable results of anti-HER2 treatments in lung cancers with HER2 aberrations, thus effective therapies in these patients represent an unmet medical need. By far, encouraging efforts towards novel treatment strategies have been made to improve the clinical outcomes of these patients. In this review, we describe the biological and clinicopathological characteristics of HER2 alterations and systematically sum up recent studies on emerging therapies for this subset of patients.
Insights
Human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer (NSCLC) present a treatment challenge. This review summarizes HER2 alterations and emerging therapies for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) harbors various molecular targets for drug development.
- Human epidermal growth factor receptor 2 (HER2, ERBB2) alterations (mutation, amplification, overexpression) represent an uncommon but significant subset.
- Effective therapies for HER2-altered NSCLC remain an unmet medical need, with modest and variable results from current anti-HER2 treatments.
Purpose of the Study:
- To review the biological and clinicopathological characteristics of HER2 alterations in NSCLC.
- To systematically summarize recent advancements in emerging therapies for HER2-altered NSCLC.
- To highlight the unmet need for effective treatments in this patient population.
Main Methods:
- Literature review of biological and clinicopathological features of HER2 alterations.
- Systematic summary of recent studies on novel therapeutic strategies.
- Analysis of clinical outcomes and treatment responses in HER2-altered NSCLC.
Main Results:
- HER2 alterations in NSCLC are heterogeneous, encompassing mutations, amplifications, and overexpression.
- Previous anti-HER2 therapies have shown limited and inconsistent efficacy in NSCLC compared to other cancers.
- Emerging therapeutic strategies show promise for improving clinical outcomes in patients with HER2-altered NSCLC.
Conclusions:
- Understanding the diverse HER2 alterations in NSCLC is crucial for targeted therapy development.
- Novel treatment strategies are actively being investigated to address the limitations of current therapies.
- Further research is needed to establish effective and durable treatments for HER2-altered NSCLC.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
